Literature DB >> 28275504

New treatment options and challenges for patients with anaplastic lymphoma kinase-positive non-small cell lung cancer with brain metastases.

Dwight Owen1, Gregory A Otterson1.   

Abstract

Entities:  

Year:  2017        PMID： 28275504      PMCID： PMC5334100          DOI： 10.21037/jtd.2017.02.06

Source DB:  PubMed          Journal:  J Thorac Dis        ISSN： 2072-1439            Impact factor:   2.895


× No keyword cloud information.
  21 in total

1.  Safety and activity of alectinib against systemic disease and brain metastases in patients with crizotinib-resistant ALK-rearranged non-small-cell lung cancer (AF-002JG): results from the dose-finding portion of a phase 1/2 study.

Authors:  Shirish M Gadgeel; Leena Gandhi; Gregory J Riely; Alberto A Chiappori; Howard L West; Michele C Azada; Peter N Morcos; Ruey-Min Lee; Linta Garcia; Li Yu; Frederic Boisserie; Laura Di Laurenzio; Sophie Golding; Jotaro Sato; Shumpei Yokoyama; Tomohiro Tanaka; Sai-Hong Ignatius Ou
Journal:  Lancet Oncol       Date:  2014-08-18       Impact factor: 41.316

2.  Alectinib's activity against CNS metastases from ALK-positive non-small cell lung cancer: a single institution case series.

Authors:  Giulio Metro; Gianluigi Lunardi; Chiara Bennati; Pietro Chiarini; Isabella Sperduti; Biagio Ricciuti; Luca Marcomigni; Cinzia Costa; Lucio Crinò; Piero Floridi; Stefania Gori; Rita Chiari
Journal:  J Neurooncol       Date:  2016-06-20       Impact factor: 4.130

3.  Brain metastases in adenocarcinoma of the lung: frequency, risk groups, and prognosis.

Authors:  J B Sørensen; H H Hansen; M Hansen; P Dombernowsky
Journal:  J Clin Oncol       Date:  1988-09       Impact factor: 44.544

4.  Pooled Analysis of CNS Response to Alectinib in Two Studies of Pretreated Patients With ALK-Positive Non-Small-Cell Lung Cancer.

Authors:  Shirish M Gadgeel; Alice T Shaw; Ramaswamy Govindan; Leena Gandhi; Mark A Socinski; D Ross Camidge; Luigi De Petris; Dong-Wan Kim; Alberto Chiappori; Denis L Moro-Sibilot; Michael Duruisseaux; Lucio Crino; Tommaso De Pas; Eric Dansin; Antje Tessmer; James Chih-Hsin Yang; Ji-Youn Han; Walter Bordogna; Sophie Golding; Ali Zeaiter; Sai-Hong Ignatius Ou
Journal:  J Clin Oncol       Date:  2016-10-31       Impact factor: 44.544

5.  Radiation necrosis presenting as pseudoprogression (PsP) during alectinib treatment of previously radiated brain metastases in ALK-positive NSCLC: Implications for disease assessment and management.

Authors:  Sai-Hong Ignatius Ou; Samuel J Klempner; Michele C Azada; Veronica Rausei-Mills; Christopher Duma
Journal:  Lung Cancer       Date:  2015-03-30       Impact factor: 5.705

6.  Clinical impact of continued crizotinib administration after isolated central nervous system progression in patients with lung cancer positive for ALK rearrangement.

Authors:  Masayuki Takeda; Isamu Okamoto; Kazuhiko Nakagawa
Journal:  J Thorac Oncol       Date:  2013-05       Impact factor: 15.609

7.  Outcomes of Gamma Knife Radiosurgery in Combination with Crizotinib for Patients with Brain Metastasis from Non-Small Cell Lung Cancer.

Authors:  Jung Won Choi; Doo-Sik Kong; Ho Jun Seol; Do-Hyun Nam; Kwai Han Yoo; Jong-Mu Sun; Jin-Seok Ahn; Myung-Ju Ahn; Keunchil Park; Jung-Il Lee
Journal:  World Neurosurg       Date:  2016-08-24       Impact factor: 2.104

8.  Local ablative therapy of oligoprogressive disease prolongs disease control by tyrosine kinase inhibitors in oncogene-addicted non-small-cell lung cancer.

Authors:  Andrew J Weickhardt; Benjamin Scheier; Joseph Malachy Burke; Gregory Gan; Xian Lu; Paul A Bunn; Dara L Aisner; Laurie E Gaspar; Brian D Kavanagh; Robert C Doebele; D Ross Camidge
Journal:  J Thorac Oncol       Date:  2012-12       Impact factor: 15.609

9.  Evaluation on efficacy and safety of the addition of X-knife therapy to gefitinib in NSCLC patients with symptomatic brain metastases.

Authors:  Linbo Cai; Xiaoguang Qiu; Haihong Yang; Mingyao Lai; Changguo Shan; Weiping Hong; Juan Li; Longhui Luo; Ping Zhang; Lichao Wang
Journal:  Oncotarget       Date:  2016-07-06

10.  Clinical data from the real world: efficacy of Crizotinib in Chinese patients with advanced ALK-rearranged non-small cell lung cancer and brain metastases.

Authors:  Puyuan Xing; Shouzheng Wang; Xuezhi Hao; Tongtong Zhang; Junling Li
Journal:  Oncotarget       Date:  2016-12-20
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.